PTP1B phosphatase as a novel target of oleuropein activity in MCF-7 breast cancer model

Toxicol In Vitro. 2019 Dec:61:104624. doi: 10.1016/j.tiv.2019.104624. Epub 2019 Aug 13.

Abstract

Phosphatase PTP1B has become a therapeutic target for the treatment of type 2-diabetes, whereas recent studies have revealed that PTP1B plays a pivotal role in pathophysiology and development of breast cancer. Oleuropein is a natural, phenolic compound with anticancer activity. The aim of this study was to address the question whether PTP1B constitutes a target for oleuropein in breast cancer MCF-7 cells. The cellular MCF-7 breast cancer model was used in the study. The experiments were performed using cellular viability tests, Elisa assays, immunoprecipitation, flow cytometry analyses and computer modelling. Herein, we evidenced that the reduced activity of phosphatase PTP1B after treatment with oleuropein is strictly correlated with decreased MCF-7 cellular viability and cell cycle arrest. These results provide new insight into further research on oleuropein and possible role of the compound in adjuvant treatment of breast cancer.

Keywords: Anticancer therapy; MCF-7 cells; Oleuropein; PTP1B phosphatase; breast cancer.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / enzymology
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Humans
  • Iridoid Glucosides
  • Iridoids / chemistry
  • Iridoids / pharmacology*
  • MCF-7 Cells
  • Molecular Dynamics Simulation
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / chemistry
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / genetics
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism*

Substances

  • Antineoplastic Agents
  • Iridoid Glucosides
  • Iridoids
  • oleuropein
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1